vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Ranpak Holdings Corp. (PACK). Click either name above to swap in a different company.

Ranpak Holdings Corp. is the larger business by last-quarter revenue ($93.7M vs $74.7M, roughly 1.3× Health Catalyst, Inc.). On growth, Ranpak Holdings Corp. posted the faster year-over-year revenue change (2.3% vs -6.2%). Over the past eight quarters, Ranpak Holdings Corp.'s revenue compounded faster (13.7% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Ranpak Holdings Corp. manufactures machines and paper products used in protective paper-based packing for shipping goods and merchandise for e-commerce and industry, along with automation solutions. The company is based in Concord, Ohio, and has production facilities and offices in Reno, Nevada; Kansas City, Missouri; the Netherlands; Czech Republic; Shanghai and Singapore. The paper packaging material can be used for multiple applications like wrapping, cushioning, void fill and cold chain p...

HCAT vs PACK — Head-to-Head

Bigger by revenue
PACK
PACK
1.3× larger
PACK
$93.7M
$74.7M
HCAT
Growing faster (revenue YoY)
PACK
PACK
+8.5% gap
PACK
2.3%
-6.2%
HCAT
Faster 2-yr revenue CAGR
PACK
PACK
Annualised
PACK
13.7%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
PACK
PACK
Revenue
$74.7M
$93.7M
Net Profit
$-91.0M
Gross Margin
39.0%
Operating Margin
-115.3%
-1.0%
Net Margin
-121.9%
Revenue YoY
-6.2%
2.3%
Net Profit YoY
-340.3%
EPS (diluted)
$-1.29
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
PACK
PACK
Q4 25
$74.7M
$93.7M
Q3 25
$76.3M
$83.6M
Q2 25
$80.7M
$77.8M
Q1 25
$79.4M
$77.6M
Q4 24
$79.6M
$91.6M
Q3 24
$76.4M
$78.6M
Q2 24
$75.9M
$72.8M
Q1 24
$74.7M
$72.5M
Net Profit
HCAT
HCAT
PACK
PACK
Q4 25
$-91.0M
Q3 25
$-22.2M
$-10.4M
Q2 25
$-41.0M
$-7.5M
Q1 25
$-23.7M
$-10.9M
Q4 24
$-20.7M
Q3 24
$-14.7M
$-8.1M
Q2 24
$-13.5M
$5.5M
Q1 24
$-20.6M
$-8.1M
Gross Margin
HCAT
HCAT
PACK
PACK
Q4 25
39.0%
Q3 25
52.6%
41.1%
Q2 25
37.1%
Q1 25
39.8%
Q4 24
45.2%
Q3 24
47.5%
43.8%
Q2 24
43.5%
Q1 24
44.6%
Operating Margin
HCAT
HCAT
PACK
PACK
Q4 25
-115.3%
-1.0%
Q3 25
-22.9%
-6.8%
Q2 25
-46.0%
-12.5%
Q1 25
-25.4%
-10.3%
Q4 24
-22.0%
1.5%
Q3 24
-17.9%
-5.3%
Q2 24
-20.8%
-7.1%
Q1 24
-30.5%
-6.6%
Net Margin
HCAT
HCAT
PACK
PACK
Q4 25
-121.9%
Q3 25
-29.1%
-12.4%
Q2 25
-50.8%
-9.6%
Q1 25
-29.9%
-14.0%
Q4 24
-26.0%
Q3 24
-19.3%
-10.3%
Q2 24
-17.8%
7.6%
Q1 24
-27.6%
-11.2%
EPS (diluted)
HCAT
HCAT
PACK
PACK
Q4 25
$-1.29
$-0.11
Q3 25
$-0.32
$-0.12
Q2 25
$-0.59
$-0.09
Q1 25
$-0.35
$-0.13
Q4 24
$-0.33
$-0.13
Q3 24
$-0.24
$-0.10
Q2 24
$-0.23
$0.07
Q1 24
$-0.35
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
PACK
PACK
Cash + ST InvestmentsLiquidity on hand
$95.7M
$63.0M
Total DebtLower is stronger
$153.3M
$401.9M
Stockholders' EquityBook value
$245.8M
$534.9M
Total Assets
$502.6M
$1.1B
Debt / EquityLower = less leverage
0.62×
0.75×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
PACK
PACK
Q4 25
$95.7M
$63.0M
Q3 25
$91.5M
$49.9M
Q2 25
$97.3M
$49.2M
Q1 25
$342.0M
$65.5M
Q4 24
$392.0M
$76.1M
Q3 24
$387.3M
$69.5M
Q2 24
$308.3M
$65.1M
Q1 24
$327.8M
$55.1M
Total Debt
HCAT
HCAT
PACK
PACK
Q4 25
$153.3M
$401.9M
Q3 25
$153.1M
$403.1M
Q2 25
$153.0M
$403.1M
Q1 25
$382.9M
$405.2M
Q4 24
$382.4M
$406.4M
Q3 24
$345.0M
$403.2M
Q2 24
$396.1M
Q1 24
$396.7M
Stockholders' Equity
HCAT
HCAT
PACK
PACK
Q4 25
$245.8M
$534.9M
Q3 25
$331.9M
$537.8M
Q2 25
$347.5M
$539.0M
Q1 25
$376.8M
$544.1M
Q4 24
$365.2M
$548.1M
Q3 24
$355.0M
$564.3M
Q2 24
$357.0M
$566.2M
Q1 24
$357.2M
$560.0M
Total Assets
HCAT
HCAT
PACK
PACK
Q4 25
$502.6M
$1.1B
Q3 25
$587.1M
$1.1B
Q2 25
$616.2M
$1.1B
Q1 25
$891.5M
$1.1B
Q4 24
$858.9M
$1.1B
Q3 24
$813.0M
$1.1B
Q2 24
$691.7M
$1.1B
Q1 24
$695.1M
$1.1B
Debt / Equity
HCAT
HCAT
PACK
PACK
Q4 25
0.62×
0.75×
Q3 25
0.46×
0.75×
Q2 25
0.44×
0.75×
Q1 25
1.02×
0.74×
Q4 24
1.05×
0.74×
Q3 24
0.97×
0.71×
Q2 24
0.70×
Q1 24
0.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
PACK
PACK
Operating Cash FlowLast quarter
$9.9M
$19.5M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
PACK
PACK
Q4 25
$9.9M
$19.5M
Q3 25
$-464.0K
$8.5M
Q2 25
$-9.0M
$-3.6M
Q1 25
$280.0K
$-1.3M
Q4 24
$-3.5M
$6.5M
Q3 24
$6.2M
$10.1M
Q2 24
$1.6M
$19.6M
Q1 24
$10.3M
$5.2M
Free Cash Flow
HCAT
HCAT
PACK
PACK
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
Q1 24
$10.1M
FCF Margin
HCAT
HCAT
PACK
PACK
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Q1 24
13.5%
Capex Intensity
HCAT
HCAT
PACK
PACK
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Q1 24
0.3%
Cash Conversion
HCAT
HCAT
PACK
PACK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
3.56×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

PACK
PACK

Other$47.9M51%
Europe And Asia Segment$45.8M49%

Related Comparisons